(Reuters) - Liver cancer is one of the most common cancer types
worldwide.
Bayer said Nexavar has the potential to become the
therapeutic standard because there is currently no approved
treatment that can demonstrably increase overall survival in
patients suffering from this disease.
Read more at Reuters.com Government Filings News
worldwide.
Bayer said Nexavar has the potential to become the
therapeutic standard because there is currently no approved
treatment that can demonstrably increase overall survival in
patients suffering from this disease.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment